Lung cancer trials in Israel

In Israel 67 Also abroad 2733

67 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Petah Tikva, Ramat Gan
Age
18 years and over
People
430 worldwide
Run by
Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Beersheba, Haifa, Jerusalem, Kfar Saba, Naharyia
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 1Taking people
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Where
Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
339 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT06179069
Phase 2Taking people
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Where
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00
No phaseTaking people
Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer
Where
Ashkelon
Age
18 years and over
People
10
Run by
Barzilai Medical Center
See details and how to joinNCT06889467
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Haifa, Tel Aviv
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 2Taking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Jerusalem, Ramat Gan
Age
18 years and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Tel Aviv
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Haifa, Jerusalem, Petah Tikva, Ramat Gan
Age
18 years and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Haifa, Ramat Gan
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Haifa, Petah Tikva, Ramat Gan
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Haifa, Kefar Sava, Petah Tikva, Ramat Gan, Tsrifin
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tsrifin
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Jerusalem, Kfar Saba, Ramat Gan
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Jerusalem, Petah Tikva
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Afula, Beersheba, Hadera, Haifa, Jerusalem, Ramat Gan, Tel Aviv
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 1Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Haifa, Jerusalem, Petah Tikva
Age
18 years and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Haifa, Tel Aviv
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 1Taking people
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Where
Haifa, Jerusalem, Ramat Gan
Age
18 years and over
People
220 worldwide
Run by
AbbVie
See details and how to joinNCT07241039 · EU 2025-521607-48-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Haifa, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Tel Aviv
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 1Taking people
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Where
Jerusalem
Age
18 years and over
People
914 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00
Phase 1Taking people
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Where
Beer Ya'akov, Haifa, Jerusalem, Kefar Sava, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
694 worldwide
Run by
AbbVie
See details and how to joinNCT05005403